File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Low molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: A randomized control trial
  • Basic View
  • Metadata View
  • XML View
TitleLow molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: A randomized control trial
 
AuthorsSiu, CW1
Jim, MH1
Lau, CP1
Tse, HF1
 
KeywordsHeparin
Stroke
 
Issue Date2011
 
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/14628848.asp
 
CitationAcute Cardiac Care, 2011, v. 13 n. 3, p. 196-198 [How to Cite?]
DOI: http://dx.doi.org/10.3109/17482941.2011.567283
 
AbstractWhile long-term anticoagulation prevents ischemic stroke in high-risk patients with atrial fibrillation (AF), the optimal initial anti-thrombotic regime in acute AF is less well defined. We randomized 96 patients with new onset acute AF in an emergency admission ward to receive (1) once-daily preparation of low molecular weight heparin (LMWH), tinzaparin or (2) conventional intravenous unfractionated heparin (target APTT 5070 s). 5 patients in unfractionated heparin group compared with no patients in LMWH group (0%, P = 0.04) developed ischemic stroke/transient ischemic attack during the first 48 h. An initial subcutaneous LMWH was safe and effective in ischemic stroke prevention in patients with acute AF. © 2011 Informa UK, Ltd.
 
ISSN1748-2941
2012 SCImago Journal Rankings: 0.308
 
DOIhttp://dx.doi.org/10.3109/17482941.2011.567283
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorSiu, CW
 
dc.contributor.authorJim, MH
 
dc.contributor.authorLau, CP
 
dc.contributor.authorTse, HF
 
dc.date.accessioned2011-07-27T01:30:22Z
 
dc.date.available2011-07-27T01:30:22Z
 
dc.date.issued2011
 
dc.description.abstractWhile long-term anticoagulation prevents ischemic stroke in high-risk patients with atrial fibrillation (AF), the optimal initial anti-thrombotic regime in acute AF is less well defined. We randomized 96 patients with new onset acute AF in an emergency admission ward to receive (1) once-daily preparation of low molecular weight heparin (LMWH), tinzaparin or (2) conventional intravenous unfractionated heparin (target APTT 5070 s). 5 patients in unfractionated heparin group compared with no patients in LMWH group (0%, P = 0.04) developed ischemic stroke/transient ischemic attack during the first 48 h. An initial subcutaneous LMWH was safe and effective in ischemic stroke prevention in patients with acute AF. © 2011 Informa UK, Ltd.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationAcute Cardiac Care, 2011, v. 13 n. 3, p. 196-198 [How to Cite?]
DOI: http://dx.doi.org/10.3109/17482941.2011.567283
 
dc.identifier.doihttp://dx.doi.org/10.3109/17482941.2011.567283
 
dc.identifier.epage198
 
dc.identifier.hkuros187310
 
dc.identifier.hkuros201287
 
dc.identifier.hkuros208713
 
dc.identifier.issn1748-2941
2012 SCImago Journal Rankings: 0.308
 
dc.identifier.issue3
 
dc.identifier.pmid21517667
 
dc.identifier.scopuseid_2-s2.0-80052453860
 
dc.identifier.spage196
 
dc.identifier.urihttp://hdl.handle.net/10722/135232
 
dc.identifier.volume13
 
dc.languageeng
 
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/14628848.asp
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofAcute Cardiac Care
 
dc.relation.referencesReferences in Scopus
 
dc.rightsAcute Cardiac Care. Copyright © Informa Healthcare.
 
dc.subject.meshAtrial Fibrillation - drug therapy - pathology
 
dc.subject.meshFibrinolytic Agents - administration and dosage - therapeutic use
 
dc.subject.meshHeparin - administration and dosage - therapeutic use
 
dc.subject.meshHeparin, Low-Molecular-Weight - administration and dosage - therapeutic use
 
dc.subject.meshInfusions, Intravenous
 
dc.subjectHeparin
 
dc.subjectStroke
 
dc.titleLow molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: A randomized control trial
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Siu, CW</contributor.author>
<contributor.author>Jim, MH</contributor.author>
<contributor.author>Lau, CP</contributor.author>
<contributor.author>Tse, HF</contributor.author>
<date.accessioned>2011-07-27T01:30:22Z</date.accessioned>
<date.available>2011-07-27T01:30:22Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Acute Cardiac Care, 2011, v. 13 n. 3, p. 196-198</identifier.citation>
<identifier.issn>1748-2941</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/135232</identifier.uri>
<description.abstract>While long-term anticoagulation prevents ischemic stroke in high-risk patients with atrial fibrillation (AF), the optimal initial anti-thrombotic regime in acute AF is less well defined. We randomized 96 patients with new onset acute AF in an emergency admission ward to receive (1) once-daily preparation of low molecular weight heparin (LMWH), tinzaparin or (2) conventional intravenous unfractionated heparin (target APTT 5070 s). 5 patients in unfractionated heparin group compared with no patients in LMWH group (0%, P = 0.04) developed ischemic stroke/transient ischemic attack during the first 48 h. An initial subcutaneous LMWH was safe and effective in ischemic stroke prevention in patients with acute AF. &#169; 2011 Informa UK, Ltd.</description.abstract>
<language>eng</language>
<publisher>Informa Healthcare. The Journal&apos;s web site is located at http://www.tandf.co.uk/journals/titles/14628848.asp</publisher>
<relation.ispartof>Acute Cardiac Care</relation.ispartof>
<rights>Acute Cardiac Care. Copyright &#169; Informa Healthcare.</rights>
<subject>Heparin</subject>
<subject>Stroke</subject>
<subject.mesh>Atrial Fibrillation - drug therapy - pathology</subject.mesh>
<subject.mesh>Fibrinolytic Agents - administration and dosage - therapeutic use</subject.mesh>
<subject.mesh>Heparin - administration and dosage - therapeutic use</subject.mesh>
<subject.mesh>Heparin, Low-Molecular-Weight - administration and dosage - therapeutic use</subject.mesh>
<subject.mesh>Infusions, Intravenous</subject.mesh>
<title>Low molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: A randomized control trial</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.3109/17482941.2011.567283</identifier.doi>
<identifier.pmid>21517667</identifier.pmid>
<identifier.scopus>eid_2-s2.0-80052453860</identifier.scopus>
<identifier.hkuros>187310</identifier.hkuros>
<identifier.hkuros>201287</identifier.hkuros>
<identifier.hkuros>208713</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-80052453860&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>13</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>196</identifier.spage>
<identifier.epage>198</identifier.epage>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong